1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Lymphoma-API Insights, 2014

Lymphoma-API Insights, 2014

  • November 2014
  • -
  • Delve Insight

Summary

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

DelveInsight’s, Lymphoma -API Insights, 2014 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Lymphoma. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales forecasts data till 2015.

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global Market therapeutics scenario for Lymphoma.
- A review of the marketed products under prescription for Lymphoma, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Lymphoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Lymphoma drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Lymphoma drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to Buy
- Evaluate the marketing status and exclusivity details of Lymphoma key products to exploit opportunities for generic drug development opportunities.
- Key players in the pharmaceutical industry.
-Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lymphoma.
- API intelligence over marketed drugs for Lymphoma and gaining primary intelligence over active ingredients manufacturers across the globe.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Lymphoma-API Insights, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Discontinued Drugs Information

List of Tables
Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Lymphoma Therapeutic Market, US, (Year), 2014
Lymphoma Marketed Drugs, API Manufacturers by US DMF Status, 2014
Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Lymphoma Therapeutic Market, Global Sales (in million USD), 2014
Lymphoma Marketed Drugs, API Manufacturers, Global, 2014
Discontinued Drugs for Lymphoma, 2014

List of Figures
Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Lymphoma Therapeutic Market, US, (Year), 2014
Lymphoma Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Lymphoma Therapeutic Market, Global Sales (in million USD), 2014
Lymphoma Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

Companies Mentioned
Cephalon, Inc.
Millennium Pharmaceuticals, Inc.
Allergan, Inc.
Horizon Pharma, Inc.
Spectrum Pharmaceuticals, Inc.
Merck and Co., Inc.
Celgene Corporation
GlaxoSmithKline plc
Pfizer Inc.
Bristol-Myers Squibb Company
Corden Pharma S.p.A.
Sigma-Tau Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals Inc.
Lilly USA, LLC
Eli Lilly and Company
Valeant Pharmaceuticals International, Inc.
Baxter Healthcare Corporation
Aspen Healthcare, Inc.
Mylan Inc.
Teva Pharmaceuticals USA, Inc.
Hospira, Inc.
Recordati S.p.A.
Shire Plc
Merck Sharp and Dohme Corp.
Abbott Laboratories
Sandoz Inc.
Panray Corporation
UCB, Inc.
Tiber Laboratories, LLC
Concordia Pharmaceuticals Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global non-Hodgkin’s lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach ...

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global T-cell lymphoma market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics and Infectious Disease Statistics in Denmark

  • January 2017
    3 pages
  • Cancer  

    Lymphoma  

    Infectious Dise...  

  • Denmark  

View report >

Lymphoma Statistics in Denmark

  • January 2017
    8 pages
  • Lymphoma  

  • Denmark  

View report >

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Related Market Segments :

Lymphoma

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.